Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM
Patients with rheumatoid arthritis (RA) may experience residual pain and functional impairment despite good control of disease activity. This study compared improvements in pain and physical function in patients with well-controlled RA after 24 weeks’ treatment with baricitinib, adalimumab or placeb...
المؤلفون الرئيسيون: | Fautrel, B, Kirkham, B, Pope, J, Takeuchi, T, Gaich, C, Quebe, A, Zhu, B, De La Torre, I, De Leonardis, F, Taylor, P |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
MDPI
2019
|
مواد مشابهة
-
Improved patient-reported outcomes in patients with rheumatoid arthritis who failed adalimumab or placebo treatment and were rescued with baricitinib
حسب: Fautrel, B, وآخرون
منشور في: (2017) -
Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial
حسب: Taylor, P, وآخرون
منشور في: (2019) -
Baricitinib versus placebo or adalimumab in rheumatoid arthritis
حسب: Taylor, P, وآخرون
منشور في: (2017) -
Rapid and concurrent improvements in patient-reported outcomes of rheumatoid arthritis with baricitinib in RA-BEAM
حسب: Strand, V, وآخرون
منشور في: (2021) -
Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
حسب: Taylor, P, وآخرون
منشور في: (2017)